Perampanel, Serum
Use
The test is useful for monitoring serum concentration of perampanel in patients with specific clinical conditions such as severe kidney impairment, mild to moderate hepatic impairment, and end-stage kidney disease. It assists in assessing compliance and potential toxicity, particularly when perampanel is coadministered with other anticonvulsant drugs. The test provides valuable insights in cases involving poor response or adverse effects, contributing to effective management of seizure disorders where perampanel is used as adjunctive therapy.
Special Instructions
Not provided.
Limitations
This test is not suitable for whole blood specimens. Interpretation should be done in the context of clinical evaluation as therapeutic ranges based on trough levels provide optimal response information. Variability outside the therapeutic range may occur, therefore continuous evaluation is required to ensure appropriate therapeutic management. This test has not been cleared or approved by the FDA.
New York Approved
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
Perampanel
Analyte
LOINC Codes
- 88895-8 - Perampanel SerPl-mCnc
- 88895-8 - Perampanel SerPl-mCnc
Result Turnaround Time
2-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plastic vial
Collection Instructions
Draw blood immediately before next scheduled dose. For sustained-release formulations ONLY, draw blood a minimum of 12 hours after last dose. Within 2 hours of collection, centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 28 days |
| Refrigerated | 28 days |
| Frozen | 28 days |